Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc.

Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.
Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.
BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.
Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.
Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.